Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapy

Area of Science:

• Cardiology
• Molecular Biology
• Genetics

Background:

• Heart failure (HF) is a major cause of death, with incidence rising due to an aging population.
• Current pharmacologic therapies for HF have limitations in restoring myocardial function.
• Dysregulation of beta-adrenergic receptor (betaAR) signaling and intracellular calcium handling are key features of failing myocardium.

Purpose of the Study:

• To review functional alterations in betaAR signaling and Ca2+-handling in HF.
• To discuss novel therapeutic strategies, particularly gene therapy, for HF treatment.
• To highlight in vivo gene therapy targeting betaARK1/GRK2 and S100A1 for cardiac support.

Main Methods:

• Review of current literature on HF pathophysiology and therapeutic interventions.
• Focus on advances in transgenic and gene therapy techniques.
• Analysis of in vivo studies employing gene therapy for HF.

Main Results:

• HF involves distinct changes in betaAR signaling and intracellular Ca2+-handling.
• Gene therapy offers novel strategies to modulate myocardial function.
• Targeted inhibition of betaARK1/GRK2 and S100A1 restoration show potential in preclinical models.

Conclusions:

• Novel gene therapy approaches targeting betaAR signaling and Ca2+-handling are needed for HF.
• Inhibition of betaARK1/GRK2 and S100A1 restoration represent promising therapeutic avenues.
• These strategies aim to support the injured heart and reverse or prevent HF progression.